Updates in Metastatic NSCLC From ASCO 2025
Dr Goldman reviews findings from TROPION-Lung02, which evaluated datopotamab deruxtecan (Dato-DXd) ± pembrolizumab (pembro) in first-line metastatic NSCLC. The objective response rate (ORR) was 55% for Dato-DXd + pembro vs 56% for chemo. Improved outcomes in TROP2 NMR-positive patients may indicate a predictive biomarker.
Dr Goldman then discusses results from OptiTROP-Lung03, in which sacituzumab tirumotecan (sac-TMT) showed superior efficacy compared to docetaxel in pretreated EGFR-mutated NSCLC. The ORR for sac-TMT was 45% vs 15% for docetaxel.
Next, he highlights updates from KRYSTAL-7 of first-line adagrasib plus pembro in KRASG12C-mutant NSCLC. The combination yielded an ORR of 44% and median duration of response of 26.3 months. In patients with a PD-L1 ≥ 50%, ORR reached 50% vs 34% in those with lower expression.
Dr Goldman also reports on HERTHENA-Lung02, in which patritumab deruxtecan (HER3-DXd) improved progression-free survival (PFS) vs chemo in resistant EGFR-mutated NSCLC, but the lack of overall survival benefit led to application withdrawal.
Finally, Dr Goldman reviews phase 2b findings from REZILIENT1, evaluating zipalertinib in EGFR exon 20-mutant NSCLC. In patients without prior amivantamab, ORR was 40% and PFS was 9.5 months. In those previously treated with amivantamab, zipalertinib resulted in clinically meaningful results: an ORR of 23.5% and PFS of 7.3 months.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
a minute ago
- Gizmodo
Scientists Identify a New Glitch in Human Thinking
Good news, everyone! Scientists at the University of California, Berkeley, have coined a new term to describe our brains being dumb. In a recent study, they provide evidence for a distinct but common kind of cognitive bias—one that makes us reluctant to take the easier path in life if it means retracing our steps. The researchers have named the bias the 'doubling-back aversion.' In several experiments, they found that people often refuse to choose a more efficient solution or route if it requires them to double back on the progress already made. The findings suggest that people's subjective fear of adding more to their workload and their hesitance to wipe the slate clean contribute to this bias, the researchers say. 'Participants' aversion to feeling their past efforts were a waste encouraged them to pursue less efficient means,' they wrote in their paper, published this May in Psychological Science. The 12 cognitive biases that prevent you from being rational Psychologists have detailed all sorts of biases related to digging our feet in when faced with important new information. People tend to stick to the status quo in choosing dinner at a favorite restaurant, for example, even when someone recommends a potentially tastier option. There's also the sunk cost fallacy, or the reluctance to veer off a disastrous path and choose another simply because they've spent so much time or resources pursuing it. The researchers argue that their newly named bias is certainly a close cousin to the sunk cost fallacy and similar biases, but that it ultimately describes a unique type of cognitive pitfall. In their paper, they provide the example of someone whose flight from San Francisco to New York becomes massively delayed early on, leaving them stuck in Los Angeles. In one scenario, the traveler can get home three hours earlier than their current itinerary if they accept the airline's offer of a new flight that first stops in Denver; in the second, the person is instead offered a flight that will also shave three hours off, but they'll first have to travel back to San Francisco. Despite both flights saving the same amount of time, people are more likely to refuse the one that requires going back to their earlier destination, the paper explains (some people might even refuse the Denver flight, but that would be an example of the status quo bias and/or sunk cost fallacy at work, they note). To test their hypothesis, the researchers ran four different types of experiments. The experiments collectively involved more than 2,500 adults, some of whom were UC Berkeley students and others who were volunteers recruited through Amazon's Mechanical Turk. In one test, people were asked to walk along different paths in virtual reality; another asked people to recite as many words starting with the same letter as possible. Across the various tests, the researchers found that people routinely exhibited this aversion. This Is What Your Brain Looks Like When You Solve a Problem In one experiment where people had to recite words starting with 'G,' for instance, everyone was asked midway through if they wanted to stay with the same letter or switch to reciting words starting with 'T' (a likely easier letter). In the control condition, this decision was framed as staying on the same task, simply with a new letter, but in the other, people were asked if they wanted to throw out the work they had done so far and start over on a new task. Importantly, the volunteers were also given progress bars for the task, allowing them to see they would perform the same amount of work no matter the choice (though again, 'T' would be easier). About 75% of participants made the choice to switch in the control condition, but only 25% did the same when the switch was presented as needing to double back. 'When I was analyzing these results, I was like, 'Oh, is there a mistake? How can there be such a big difference?'' said lead author Kristine Cho, a behavioral marketing PhD student at UC Berkely's Haas School of Business, in a statement to the Association for Psychological Science, publishers of the study. Other researchers will have to confirm the team's findings, of course. And there are still plenty of questions to answer about this aversion, including how often we fall for it and whether it's more likely to happen in some scenarios than others. But for now, it's oddly comforting to know that there's another thing I can possibly blame for my occasional stubbornness to take the faster subway train home.
Yahoo
30 minutes ago
- Yahoo
The spice linked to low blood sugar and gum disease prevention
HOLD FOR PUB UNTIL FRI Cloves can do much more than just sweeten your baked goods. Used for thousands of years in traditional medicine, the warm spice commonly used in pumpkin pie and mulled wine may also benefit your gum health and lower your blood pressure, according to years of research. 'The antibacterial properties of cloves help kill harmful bacteria inside your mouth,' Idaho's Summit Dental Group explains. 'This makes cloves highly effective in controlling plaque and reducing the risk of gum disease.' Clove oil serves as a natural antimicrobial substance, stopping the growth of bacteria and fungi, according to studies. Just a few drops are enough. People shouldn't add more than 10 to 15 drops in an ounce of water, according to the National Association for Holistic Aromatherapy. Clove oil can be an irritant for some people, particularly on the skin. This is because cloves contain eugenol, a yellow-colored compound commonly found in cinnamon and bay leaves. Eugenol affects the our ability to stop bleeding, according to the Cleveland Clinic. It can be harmful when adults take as little as 10 milliliters of eugenol, according to Mount Sinai. Children should not consume it. Still, eugenol is generally safe in the quantities found in food products made with ground cloves. Most pumpkin pie recipes don't call for more than a teaspoon of the spice. Eugenol has the ability to kill yeast, which can be the result of an overgrowth of fungus in the mouth. The compound is also what researchers say can lower your blood sugar levels. After taking 250 milligrams of clove extract daily for 30 days, researchers said participants in a 2019 study had significantly lower blood sugar after meals. Cloves are also packed with essential minerals. The spice has calcium to maintain strong bones, magnesium that can regulate blood sugar and calcium levels, potassium that helps the nerves and supports heart health, and vitamin K, which helps keep arteries healthy. Eugenol may help improve bone mass as well, according to research on animals. Lastly, cloves are a natural antioxidant, the substances found in foods that can prevent damage to cells and DNA. Experts say people need a variety of antioxidant-rich foods each day, such as berries and nuts. 'Antioxidants are almost like a shield around your cells, like a blanket around them to protect them from oxidative damage,' registered dietitian Julia Zumpano explained to the Cleveland Clinic.
Yahoo
30 minutes ago
- Yahoo
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025 and is projected to advance at a resilient CAGR of 13.9% from 2025 to 2030, culminating in a forecasted valuation of US$4.29 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. The significant rise in oncology research has increased the demand for flow cytometry products and services. Additionally, the integration of AI and machine learning is enhancing data analysis capabilities, further fueling market growth. Download PDF Brochure: Browse in-depth TOC on "Epigenetics Market" 365 - Tables45 - Figures353 - Pages By offering, the global epigenetics market is segmented into various categories, including kits and reagents, enzymes, instruments and accessories, software, and services. Within the kits and reagents category, there are sub-segments such as antibodies, chip-sequencing kits and reagents, bisulfite conversion kits and reagents, whole-genome amplification kits and reagents, 5-HMC and 5-MC analysis kits and reagents, histones, as well as other kits and reagents. In 2024, the Antibodies segment is projected to command the largest market share. This is attributed to the increasing reliance on antibodies for the detection, identification, and modification of proteins, along with their essential function in monitoring cellular regulation and gene expression. Consequently, the growth of the antibodies segment is expected to accelerate throughout the forecast period due to these advancements. By Method, the epigenetics market segmentation by methodology includes DNA methylation, histone modifications, and additional approaches such as non-coding RNA interactions and chromatin remodeling. The DNA methylation segment is projected to exhibit a robust compound annual growth rate (CAGR) throughout the forecast period, primarily driven by its proven effectiveness in oncology research applications. By geography, The Asia Pacific region is projected to experience the most rapid growth within the epigenetics market. This expansion is driven by the increasing global footprint of local companies through strategic alliances and collaborations, alongside continuous enhancements in healthcare infrastructure in emerging economies. Moreover, there is a heightened emphasis on advancing capabilities in Next-Generation Sequencing (NGS), which is further propelling market development in the region. Request Sample Pages : Key players in the epigenetics market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), QIAGEN (Germany), among others. Illumina Inc (US): In 2024, Illumina, Inc. maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation sequencing (NGS) domain, which affords it a competitive edge when exploring adjacent sectors, such as epigenetic sequencing. A notable move in this direction occurred in June 2025, when Illumina announced its acquisition of SomaLogic. This strategic acquisition is poised to bolster Illumina's footprint in the burgeoning epigenetics market and further its multiomics strategy, integrating diverse biological data for enhanced insights into genomics, transcriptomics, proteomics, and epigenomics. Thermofisher Scientific Inc. (US) Thermo Fisher Scientific Inc. (US) stands out as a prominent player in the epigenetics market in 2024, driven by a robust and diversified product portfolio, an extensive global footprint, and a strategic focus on both organic and inorganic growth initiatives. Notably, in July 2025, the company secured US Food and Drug Administration (FDA) approval for the Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay designed for companion diagnostics (CDx) in tumor profiling applications. Thermo Fisher demonstrates a strong commitment to research and development, channeling significant resources into innovation to address the dynamic needs of its clientele. Their comprehensive global distribution network enhances accessibility and customer support, facilitating the delivery of advanced and reliable epigenetics solutions. This multifaceted strategic approach solidifies Thermo Fisher's position as a leading provider in the epigenetics landscape. For more information, Inquire Now! Related Reports: Research Antibodies & Reagents Market Genomics Market Next Generation Sequencing Market PCR Technologies Market Digital PCR and qPCR Market Get access to the latest updates on Epigenetics Companies and Epigenetics Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
